Obesity Drug Study Points to Effectiveness in Curbing Addictions
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their impact on the brain, pointing to benefits from addiction to schizophrenia.
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
BioPharma Dive3d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
Obesity rate drops in the U.S., healthcare experts point to GLP-1 medications as the cause
For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...
Billed as nonaddictive, new pain pill could soon win FDA approval
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
BioWorld11d
Verdiva joins crowded GLP-1 space, launches with $411M series A
New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...
EurekAlert!13d
GLP-1 RA medications safe and very effective for treating obesity in adults without diabetes
A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...
Tyler Morning Telegraph18d
Jarvis: The bar for successful obesity drugs is rising
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s ...
Business Insider18d
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Developing brand new drugs is a long ... buying smaller biotechs developing drugs in major markets such as obesity and oncology. 2025's top drug targets Obesity is positioned to be biopharma's ...
bnnbloomberg18d
Why the Obesity Drug Revolution Is a Work in Progress
(Bloomberg) -- A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the ...
Forbes18d
GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet
Overall, average healthcare costs increased 46% over two years for patients trying GLP-1 drugs for obesity, from $12,695 to $18,507. The Congressional Budget Office states that there does not ...
Mint19d
It’s getting harder to claim success with weight reduction drugs
The drug-maker’s own target was higher and market expectation have risen sharply in the past few years. In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people ...